Key result
PTP1B inactivation in aged mice reduced left ventricular fibrosis (5% vs 16% in wild-type, P<0.001) and improved systolic and diastolic function.
Why the study?
Does PTP1B inactivation limit aging-associated heart failure and cardiovascular dysfunction in mice?
Does PTP1B inactivation limit aging-associated heart failure and cardiovascular dysfunction in mice?
Absolute Event Rate: 5% vs 16%
p-value: p=< 0.001
PTP1B inactivation in aged mice improves left ventricular systolic and diastolic function, reduces adverse cardiac remodeling, and limits vascular endothelial dysfunction, suggesting a potential therapeutic target for age-related cardiovascular disease.
PTP1B inactivation mitigates age-related cardiac dysfunction in mice; leaves open its viability as a human HF target.
We have previously shown that protein tyrosine phosphatase 1B (PTP1B) inactivation in mice [PTP1B-deficient (PTP1B −/− ) mice] improves left ventricular (LV) angiogenesis, perfusion, remodeling, and function and limits endothelial dysfunction after myocardial infarction. However, whether PTP1B inactivation slows aging-associated cardiovascular dysfunction remains unknown. Wild-type (WT) and PTP1B −/− mice were allowed to age until 18 mo. Compared with old WT mice, in which aging increased the LV mRNA expression of PTP1B, old PTP1B −/− mice had 1) reduced cardiac hypertrophy with decreased LV mRNA levels of hypertrophic markers and atrial and brain natriuretic peptides, 2) lower LV fibrosis (collagen: 16 ± 3% in WT mice and 5 ± 3% in PTP1B −/− mice, P < 0.001) with decreased mRNA levels of transforming growth-factor-β 1 and matrix metalloproteinase-2, and 3) higher LV capillary density and lower LV mRNA level of hypoxic inducible factor-1α, which was associated over time with a higher rate of proangiogenic M2 type macrophages and a stable LV mRNA level of VEGF receptor-2. Echocardiography revealed an age-dependent LV increase in end-diastolic volume in WT mice together with alterations of fractional shortening and diastole (transmitral Doppler E-to-A wave ratio). Invasive hemodynamics showed better LV systolic contractility and better diastolic compliance in old PTP1B −/− mice (LV end-systolic pressure-volume relation: 13.9 ± 0.9 in WT mice and 18.4 ± 1.6 in PTP1B −/− mice; LV end-diastolic pressure-volume relation: 5.1 ± 0.8 mmHg/relative volume unit in WT mice and 1.2 ± 0.3 mmHg/relative volume unit in PTP1B −/− mice, P < 0.05). In addition, old PTP1B −/− mice displayed a reduced amount of LV reactive oxygen species. Finally, in isolated resistance mesenteric arteries, PTP1B inactivation reduced aging-associated endothelial dysfunction (flow-mediated dilatation: −0.4 ± 2.1% in WT mice and 8.2 ± 2.8% in PTP1B −/− mice, P < 0.05). We conclude that PTP1B inactivation slows aging-associated LV remodeling and dysfunction and reduces endothelial dysfunction in mesenteric arteries. NEW & NOTEWORTHY The present study shows that protein tyrosine phosphatase 1B inactivation in aged mice improves left ventricular systolic and diastolic function associated with reduced adverse cardiac remodeling (hypertrophy, fibrosis, and capillary rarefaction) and limits vascular endothelial dysfunction. This suggests that protein tyrosine phosphatase 1B inhibition could be an interesting treatment approach in age-related cardiovascular dysfunction.
No takes yet. Share an insight, caveat, or question.
Besnier et al. (2018) studied Aging-associated cardiovascular dysfunction. PTP1B inactivation vs. Wild-type mice was evaluated on Left ventricular fibrosis (collagen) (p=< 0.001). PTP1B inactivation in aged mice reduced left ventricular fibrosis (5% vs 16% in wild-type, P<0.001) and improved systolic and diastolic function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: